Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Use Disorder

Ahmed, Saeed; Stanciu, Cornel N.; Kotapati, Padma; Ahmed, Rizwan; Bhivandkar, Siddhi; Khan, Ali Mahmood; Afridi, Asma; Qureshi, Mustafa; Esang, Michael

doi:10.4088/pcc.19r02465

Cited by 29 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our analysis, gabapentinoids have no significant effect on craving. This differs to the finding of S. Ahmed et al (2019). We noticed two different aspects between the previous meta‐analysis and ours: (1) We focused on the delta values of pre‐ and post‐treatment craving level and performed an intergroup analysis between individuals with and without gabapentinoids treatment.…”

Section: Discussioncontrasting

confidence: 99%

“…We found that gabapentinoids are helpful in the treatment of acute alcohol withdrawal symptoms; it was also similar to the result of S. Ahmed et al (2019). It was true for the situations “only GBP” and “combining GBP and PGB”.…”

Section: Discussionsupporting

confidence: 90%

“…Some studies have also explored the effects of GBP and PGB on depression and insomnia in AUD patients (Malcolm, Myrick, Veatch, Boyle, & Randall, 2007; Mason et al, 2014; Mason, Quello, & Shadan, 2018; Wilming et al, 2018) and adverse reactions to these drugs (Di Nicola et al, 2010; Mason, Light, Williams, & Drobes, 2009; Rustembegovic, Sofic, Tahirovic, & Kundurovic, 2004; Voris et al, 2003). On the same time of performing this analysis in 2019, we noticed that two meta‐analyses about the application of GBP on AUDs were published; GBP were found to be effectively reducing heavy drinking days, withdrawal, and craving (S. Ahmed et al, 2019; Kranzler, Feinn, Morris, & Hartwell, 2019). But the approaches of those two articles were somewhat different to ours, such as the different included studies and statistical methods, not analyzing the additional effects on depression, sleep disturbance and adverse reactions, and not considering PGB studies.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta‐analysis

Cheng

Huang

2020

Human Psychopharmacology

View full text Add to dashboard Cite

Objective Gabapentin (GBP) and pregabalin (PGB) have been used to treat alcohol use disorder (AUD) and alcohol withdrawal, but with inconsistent results. In this meta‐analysis, we explored the effects of GBP/PGB treatment on AUD and their effects on withdrawal, craving, depression, and sleep disturbance in AUD patients. Methods We carried out a systematic review and meta‐analysis of randomized controlled trials comparing the effects of GBP/PGB on AUD with those of a placebo or control treatment. Electronic databases were searched for relevant articles published before September 2019. The primary outcome was defined as the efficacy measure on achieving abstinence or reducing alcohol consumption in a hierarchical order. We included 16 studies in our meta‐analysis. Results Overall, GBP had no significant benefit comparing to placebo or control treatment (Hedges' g = 0.0725, p = 0.6743). For specific alcohol‐related outcome, GBP had significant effect on percentage of heavy drink (Hedges' g = 0.5478, p = 0.0441) and alcohol withdrawal symptoms (Hedges' g = 0.2475, p = 0.0425). GBP/PGB did not have significant beneficial effect on craving, depressive symptoms, or sleep disturbance. Instability was shown in sensitivity analyses of some above results. Conclusions GBP may be helpful to reduce AUD patients' heavy drinking behavior and withdrawal, but more studies are needed for drawing conclusions.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta‐analysis

Cheng

Huang

2020

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…It is FDA-approved for the treatment of neuropathic pain, post-herpetic neuralgia, and partial seizures, but has been widely used off-label for various indications including fibromyalgia. There is increasing evidence for its use in alcohol use disorder, primarily for the treatment of withdrawal (60). Gabapentin has also been prescribed offlabel for anxiety despite a lack of research evidence supporting such use (61).…”

Section: Current Treatments For Anxiety Disordersmentioning

confidence: 99%

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options

Garakani¹,

Murrough²,

Freire³

et al. 2021

FOC

View full text Add to dashboard Cite

Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of disability. While there continues to be expansive research in posttraumatic stress disorder (PTSD), depression and schizophrenia, there is a relative dearth of novel medications under investigation for anxiety disorders. This review's first aim is to summarize current pharmacological treatments (both approved and off-label) for panic disorder (PD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and specific phobias (SP), including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), azapirones (e.g., buspirone), mixed antidepressants (e.g., mirtazapine), antipsychotics, antihistamines (e.g., hydroxyzine), alpha-and beta-adrenergic medications (e.g., propranolol, clonidine), and GABAergic medications (benzodiazepines, pregabalin, and gabapentin). Posttraumatic stress disorder and obsessive-compulsive disorder are excluded from this review. Second, we will review novel pharmacotherapeutic agents under investigation for the treatment of anxiety disorders in adults. The pathways and neurotransmitters reviewed include serotonergic agents, glutamate modulators, GABAergic medications, neuropeptides, neurosteroids, alpha-and beta-adrenergic agents, cannabinoids, and natural remedies. The outcome of the review reveals a lack of randomized double-blind placebocontrolled trials for anxiety disorders and few studies comparing novel treatments to existing anxiolytic agents. Although there are some recent randomized controlled trials for novel agents including neuropeptides, glutamatergic agents (such as ketamine and d-cycloserine), and cannabinoids (including cannabidiol) primarily in GAD or SAD, these trials have largely been negative, with only some promise for kava and PH94B (an inhaled neurosteroid). Overall, the progression of current and future psychopharmacology research in anxiety disorders suggests that there needs to be further expansion in research of these novel pathways and largerscale studies of promising agents with positive results from smaller trials.

show abstract

“…Also, among the substance-abusing populace, GPs demonstrate positive benefit in terms of amelioration of withdrawal symptoms from alcohol (EBM-levels II-Ia [15][16][17][18][19]) or opioid dependence (EBM-levels II-Ib) [19,20]) and per one randomized trial, also cannabis dependence (EBMlevel Ib [21]). This is important from a clinical standpoint in that withdrawal is one of the main triggers for relapse to substance dependence, and in that context, GP may serve as a significant therapeutic modality in addiction medicine Fig.…”

Section: Dear Editorsmentioning

confidence: 99%

Comment on “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”

Bonnet

McAnally

Scherbaum

2021

Drugs

View full text Add to dashboard Cite

Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Use Disorder

Cited by 29 publications

References 0 publications

Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta‐analysis

Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta‐analysis

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options

Comment on “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”

Contact Info

Product

Resources

About